Literature DB >> 23468111

CD1d and natural killer T cells in immunity to Mycobacterium tuberculosis.

Pooja Arora1, Erin L Foster, Steven A Porcelli.   

Abstract

The critical role of peptide antigen-specific T cells in controlling mycobacterial infections is well documented in natural resistance and vaccine-induced immunity against Mycobacterium tuberculosis. However, many other populations of leukocytes contribute to innate and adaptive immunity against mycobacteria. Among these, non-conventional T cells recognizing lipid antigens presented by the CD1 antigen presentation system have attracted particular interest. In this chapter, we review the basic immunobiology and potential antimycobacterial properties of a subset of CD1-restricted T cells that have come to be known as Natural Killer T cells. This group of lipid reactive T cells is notable for its high level of conservation between humans and mice, thus enabling a wide range of highly informative studies in mouse models. As reviewed below, NKT cells appear to have subtle but potentially significant activities in the host response to mycobacteria. Importantly, they also provide a framework for investigations into other types of lipid antigen-specific T cells that may be more abundant in larger mammals such as humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23468111     DOI: 10.1007/978-1-4614-6111-1_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  12 in total

Review 1.  Latent tuberculosis infection: myths, models, and molecular mechanisms.

Authors:  Noton K Dutta; Petros C Karakousis
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

Review 2.  The mycobacterial cell envelope-lipids.

Authors:  Mary Jackson
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-07       Impact factor: 6.915

Review 3.  Innate immunity in tuberculosis: host defense vs pathogen evasion.

Authors:  Cui Hua Liu; Haiying Liu; Baoxue Ge
Journal:  Cell Mol Immunol       Date:  2017-09-11       Impact factor: 11.530

4.  Distinct MHC class I-like interacting invariant T cell lineage at the forefront of mycobacterial immunity uncovered in Xenopus.

Authors:  Eva-Stina Edholm; Maureen Banach; Kun Hyoe Rhoo; Martin S Pavelka; Jacques Robert
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-02       Impact factor: 11.205

5.  Transcriptional profiling of Mycobacterium tuberculosis replicating ex vivo in blood from HIV- and HIV+ subjects.

Authors:  Michelle B Ryndak; Krishna K Singh; Zhengyu Peng; Susan Zolla-Pazner; Hualin Li; Lu Meng; Suman Laal
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

6.  Protective effect of a lipid-based preparation from Mycobacterium smegmatis in a murine model of progressive pulmonary tuberculosis.

Authors:  Maria de los Angeles García; Reinier Borrero; Maria E Lanio; Yanely Tirado; Nadine Alvarez; Alina Puig; Alicia Aguilar; Liem Canet; Dulce Mata Espinoza; Jorge Barrios Payán; María Elena Sarmiento; Rogelio Hernández-Pando; Mohd-Nor Norazmi; Armando Acosta
Journal:  Biomed Res Int       Date:  2014-12-07       Impact factor: 3.411

7.  Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells.

Authors:  Manjunatha M Venkataswamy; Tony W Ng; Shalu S Kharkwal; Leandro J Carreño; Alison J Johnson; Shajo Kunnath-Velayudhan; Zheng Liu; Robert Bittman; Peter J Jervis; Liam R Cox; Gurdyal S Besra; Xiangshu Wen; Weiming Yuan; Moriya Tsuji; Xiangming Li; David D Ho; John Chan; Sunhee Lee; Richard Frothingham; Barton F Haynes; Michael W Panas; Geoffrey O Gillard; Jaimie D Sixsmith; Birgit Korioth-Schmitz; Joern E Schmitz; Michelle H Larsen; William R Jacobs; Steven A Porcelli
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

Review 8.  T-Cell Therapy: Options for Infectious Diseases.

Authors:  Shreemanta K Parida; Thomas Poiret; Liu Zhenjiang; Qingda Meng; Jan Heyckendorf; Christoph Lange; Aditya S Ambati; Martin V Rao; Davide Valentini; Giovanni Ferrara; Elena Rangelova; Ernest Dodoo; Alimuddin Zumla; Markus Maeurer
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

Review 9.  Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents.

Authors:  Leandro J Carreño; Noemí A Saavedra-Ávila; Steven A Porcelli
Journal:  Clin Transl Immunology       Date:  2016-04-08

Review 10.  Early clearance versus control: what is the meaning of a negative tuberculin skin test or interferon-gamma release assay following exposure to Mycobacterium tuberculosis?

Authors:  Erin W Meermeier; David M Lewinsohn
Journal:  F1000Res       Date:  2018-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.